HS
HighVista Strategies LLC
13F filer · CIK 0001335325Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$439MU.S. long equity reported on 13F
Positions14729 new · 38 closed
Net flow last quarter-$2.25MBuys minus sells
Top 10 positions weight28.2%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 2026147 positions | |||||
| $28.2M | 6.43% | 1.78% | Not reported | Q4 2018 | |
| $15.1M | 3.43% | 0.14% | -0.2% | Q1 2024 | |
| $12.5M | 2.86% | 0.03% | -3.4% | Q1 2021 | |
| $11.4M | 2.60% | 0.18% | +30.7% | Q1 2026 | |
| $10.7M | 2.44% | 0.13% | +23.4% | Q3 2020 | |
| $10.1M | 2.31% | 0.11% | +14.8% | Q3 2024 | |
| $9.47M | 2.16% | 0.23% | +20.0% | Q4 2020 | |
| $9.39M | 2.14% | 0.11% | +144.9% | Q4 2024 | |
| $8.7M | 1.98% | 0.10% | +20.1% | Q2 2022 | |
| $8.13M | 1.85% | 0.15% | +149.6% | Q1 2026 | |
| $7.81M | 1.78% | 0.11% | -1.9% | Q2 2024 | |
| $7.31M | 1.67% | 0.11% | -4.2% | Q3 2022 | |
| $7.02M | 1.60% | 0.06% | +5.6% | Q3 2023 | |
| $7M | 1.60% | 0.19% | +88.6% | Q2 2023 | |
| $6.93M | 1.58% | 0.35% | +9.7% | Q2 2023 | |
| $6.91M | 1.57% | 0.09% | -46.8% | Q4 2023 | |
| $6.86M | 1.57% | 0.74% | +21.8% | Q4 2025 | |
| $6.65M | 1.52% | 0.06% | +33.0% | Q4 2020 | |
| $6.3M | 1.44% | 1.10% | Not reported | Q1 2021 | |
| $5.9M | 1.35% | 0.31% | +40.7% | Q2 2024 | |
| $5.63M | 1.28% | Not reported | +77.1% | Q1 2026 | |
| $5.55M | 1.27% | 0.25% | +64.0% | Q1 2024 | |
| $5.48M | 1.25% | 0.20% | +65.9% | Q1 2021 | |
| $5.25M | 1.20% | 0.27% | +1.9% | Q4 2025 | |
| $4.98M | 1.14% | 0.09% | +43.7% | Q3 2024 | |
| $4.94M | 1.13% | 0.20% | -10.1% | Q1 2021 | |
| $4.94M | 1.13% | 0.04% | -1.2% | Q2 2020 | |
| $4.9M | 1.12% | 0.09% | +137.4% | Q1 2021 | |
| $4.54M | 1.04% | 0.15% | +53.0% | Q3 2023 | |
| $4.36M | 0.99% | 0.00% | -2.8% | Q2 2024 | |
| $4.27M | 0.97% | 0.26% | -25.5% | Q4 2021 | |
| $4.24M | 0.97% | 1.17% | +0.6% | Q4 2025 | |
| $4.23M | 0.96% | 0.01% | -7.3% | Q2 2020 | |
| $4.08M | 0.93% | 0.25% | +36.8% | Q4 2025 | |
| $4.01M | 0.91% | 0.19% | -7.5% | Q2 2021 | |
| $3.99M | 0.91% | 0.07% | -46.9% | Q1 2026 | |
| $3.82M | 0.87% | 0.10% | -6.0% | Q4 2020 | |
| $3.7M | 0.84% | 0.08% | -1.0% | Q2 2021 | |
| $3.66M | 0.83% | 0.26% | -3.1% | Q1 2023 | |
| $3.33M | 0.76% | 0.01% | +28.5% | Q2 2020 | |
| $3.24M | 0.74% | 0.11% | -2.7% | Q3 2020 | |
| $3.19M | 0.73% | 0.00% | -40.2% | Q1 2016 | |
| $3.14M | 0.72% | 0.43% | +35.1% | Q1 2026 | |
| $3.13M | 0.71% | 0.02% | +161.3% | Q4 2024 | |
| $3.08M | 0.70% | 0.42% | Not reported | Q2 2020 | |
| $3M | 0.68% | 0.04% | -27.7% | Q2 2021 | |
| $2.94M | 0.67% | 0.05% | -11.5% | Q4 2024 | |
| $2.94M | 0.67% | 0.14% | +19.1% | Q1 2022 | |
| $2.67M | 0.61% | 0.00% | -34.3% | Q2 2016 | |
| $2.32M | 0.53% | 0.10% | +84.0% | Q2 2025 | |
| Q1 2026Reported May 15, 2026156 positions | |||||
| $30.6M | 8.45% | 1.81% | Not reported | Q4 2018 | |
| $12.6M | 3.48% | 0.14% | +56.9% | Q1 2024 | |
| $8.48M | 2.34% | 0.09% | +1.9% | Q3 2024 | |
| $7.58M | 2.09% | 0.12% | -41.5% | Q3 2022 | |
| $7.38M | 2.04% | 0.19% | -22.3% | Q4 2023 | |
| $7.24M | 2.00% | 0.09% | +9.3% | Q2 2022 | |
| $6.74M | 1.86% | 0.03% | -42.4% | Q1 2021 | |
| TPTERNTerns Pharmaceuticals, Inc. | $6.03M | 1.66% | 0.10% | -34.9% | Q3 2022 |
| $5.97M | 1.65% | 0.06% | -35.8% | Q3 2023 | |
| NNUVLNuvalent, Inc. | $5.8M | 1.60% | 1.81% | -22.8% | Q1 2023 |
| $5.59M | 1.54% | 0.11% | +1.5% | Q3 2020 | |
| STSLNOSoleno Therapeutics Inc | $5.53M | 1.53% | 0.32% | +22.3% | Q1 2024 |
| $5.03M | 1.39% | 0.22% | +274.2% | Q2 2024 | |
| $4.89M | 1.35% | 0.32% | +47.4% | Q2 2023 | |
| $4.66M | 1.29% | 0.00% | +28.7% | Q1 2016 | |
| $4.28M | 1.18% | 0.61% | +23.9% | Q4 2025 | |
| $4.2M | 1.16% | 0.22% | -22.6% | Q4 2020 | |
| $3.98M | 1.10% | 0.01% | -38.3% | Q2 2020 | |
| $3.91M | 1.08% | 0.00% | +57.7% | Q2 2024 | |
| $3.87M | 1.07% | 0.16% | New | Q1 2026 | |
| $3.87M | 1.07% | 0.05% | -48.8% | Q4 2020 | |
| $3.76M | 1.04% | 0.11% | -36.1% | Q2 2024 | |
| $3.74M | 1.03% | 0.20% | +28.3% | Q2 2021 | |
| $3.68M | 1.02% | 0.12% | -2.1% | Q1 2021 | |
| $3.68M | 1.02% | 0.03% | -38.2% | Q2 2021 | |
| $3.62M | 1.00% | 0.37% | Not reported | Q1 2023 | |
| $3.59M | 0.99% | 0.01% | +37.1% | Q2 2020 | |
| $3.57M | 0.99% | 0.05% | -54.0% | Q2 2021 | |
| $3.53M | 0.98% | 1.21% | +55.3% | Q4 2025 | |
| $3.51M | 0.97% | 0.18% | New | Q1 2026 | |
| $3.51M | 0.97% | 0.22% | Not reported | Q1 2021 | |
| $3.45M | 0.95% | 0.04% | +83.6% | Q2 2020 | |
| $3.42M | 0.94% | 0.32% | New | Q1 2026 | |
| $3.32M | 0.92% | 0.11% | +206.7% | Q4 2020 | |
| ATAPGEApogee Therapeutics, Inc. | $3.01M | 0.83% | 0.05% | -59.9% | Q1 2024 |
| $3M | 0.83% | 0.34% | -11.4% | Q4 2021 | |
| $2.99M | 0.82% | 0.07% | -26.6% | Q3 2024 | |
| $2.98M | 0.82% | 0.20% | -41.4% | Q4 2025 | |
| $2.93M | 0.81% | 0.06% | Not reported | Q4 2024 | |
| $2.9M | 0.80% | 0.09% | -46.3% | Q2 2021 | |
| $2.87M | 0.79% | 0.12% | -11.4% | Q2 2023 | |
| $2.85M | 0.79% | 0.05% | Not reported | Q2 2020 | |
| $2.84M | 0.78% | 0.13% | +72.6% | Q3 2020 | |
| $2.79M | 0.77% | 0.11% | Not reported | Q3 2023 | |
| $2.76M | 0.76% | 0.15% | -39.7% | Q1 2024 | |
| $2.63M | 0.72% | 0.13% | -64.0% | Q1 2022 | |
| $2.59M | 0.71% | 0.04% | +177.2% | Q4 2024 | |
| $2.49M | 0.69% | Not reported | New | Q1 2026 | |
| $2.39M | 0.66% | 0.00% | -1.2% | Q2 2013 | |
| $2.36M | 0.65% | 0.22% | New | Q1 2026 | |
| Q4 2025Reported Feb 17, 2026145 positions | |||||
| $23.6M | 6.09% | 1.84% | -26.4% | Q4 2018 | |
| $13.4M | 3.46% | 0.09% | -18.3% | Q3 2023 | |
| $12M | 3.08% | 0.21% | -27.2% | Q3 2022 | |
| $11.6M | 2.99% | 0.37% | -20.6% | Q1 2022 | |
| $9.73M | 2.51% | 0.09% | -60.9% | Q1 2024 | |
| $9.58M | 2.47% | 0.06% | -31.5% | Q1 2021 | |
| $7.62M | 1.96% | 0.10% | -72.8% | Q3 2024 | |
| NNUVLNuvalent, Inc. | $7.37M | 1.90% | 2.34% | -21.5% | Q1 2023 |
| $7.28M | 1.87% | 0.09% | -13.8% | Q4 2020 | |
| TPTERNTerns Pharmaceuticals, Inc. | $7.09M | 1.83% | 0.16% | Not reported | Q3 2022 |
| $7.06M | 1.82% | 0.35% | New | Q4 2025 | |
| $6.86M | 1.77% | 0.02% | -21.1% | Q2 2020 | |
| ATAPGEApogee Therapeutics, Inc. | $6.74M | 1.73% | 0.13% | -16.7% | Q1 2024 |
| $6.42M | 1.65% | 0.12% | -39.6% | Q2 2021 | |
| STSLNOSoleno Therapeutics Inc | $6.25M | 1.61% | 0.26% | +622.3% | Q1 2024 |
| $6.17M | 1.59% | 0.24% | -12.8% | Q4 2023 | |
| $6.13M | 1.58% | 0.04% | -2.1% | Q2 2021 | |
| $6.04M | 1.55% | 0.30% | -44.8% | Q1 2021 | |
| $5.64M | 1.45% | 0.11% | -12.3% | Q3 2020 | |
| $5.38M | 1.39% | 0.18% | -11.6% | Q2 2024 | |
| $5.26M | 1.36% | 0.09% | +31.4% | Q2 2022 | |
| CTCDTXCidara Therapeutics, Inc. | $5.06M | 1.30% | 0.07% | -67.7% | Q3 2020 |
| AACLXArcellx, Inc. | $4.89M | 1.26% | 0.13% | -22.0% | Q1 2023 |
| $4.61M | 1.19% | 0.31% | +126.7% | Q4 2020 | |
| $4.59M | 1.18% | 0.06% | +14.4% | Q2 2020 | |
| $4.52M | 1.16% | 0.15% | -40.7% | Q2 2025 | |
| $4.51M | 1.16% | 0.25% | Not reported | Q1 2024 | |
| $4.39M | 1.13% | 0.13% | +115.5% | Q1 2021 | |
| $4.25M | 1.09% | 0.16% | -17.8% | Q2 2021 | |
| $4.18M | 1.08% | 0.16% | +222.7% | Q2 2021 | |
| $4.02M | 1.04% | 0.25% | -24.4% | Q1 2025 | |
| $4.02M | 1.03% | 0.00% | -34.1% | Q1 2016 | |
| APAPLSApellis Pharmaceuticals, Inc. | $3.79M | 0.98% | 0.12% | +3.5% | Q3 2021 |
| $3.75M | 0.97% | 0.03% | -43.1% | Q4 2024 | |
| $3.67M | 0.94% | 0.20% | Not reported | Q2 2020 | |
| $3.44M | 0.89% | 0.52% | New | Q4 2025 | |
| $3.16M | 0.81% | 0.00% | -30.9% | Q2 2013 | |
| $3.12M | 0.80% | 0.55% | New | Q4 2025 | |
| $3.06M | 0.79% | 0.82% | New | Q4 2025 | |
| $3.05M | 0.79% | 0.39% | -0.6% | Q4 2021 | |
| $3.02M | 0.78% | 0.01% | -11.8% | Q2 2020 | |
| XRXOMAXOMA Royalty Corp | $3M | 0.77% | 0.95% | +6.8% | Q1 2023 |
| $2.89M | 0.74% | 0.00% | Not reported | Q2 2013 | |
| ABRNAMAvidity Biosciences, Inc. | $2.89M | 0.74% | 0.03% | -39.0% | Q3 2020 |
| $2.88M | 0.74% | 0.22% | Not reported | Q2 2023 | |
| $2.87M | 0.74% | 0.29% | New | Q4 2025 | |
| $2.65M | 0.68% | 0.00% | +6.1% | Q2 2024 | |
| $2.28M | 0.59% | 0.00% | -33.2% | Q2 2022 | |
| $2.21M | 0.57% | 0.00% | -20.0% | Q2 2013 | |
| $2.19M | 0.56% | 0.18% | New | Q4 2025 | |
| Q3 2025Reported Nov 14, 2025148 positions | |||||
| $32.4M | 7.93% | 2.50% | Not reported | Q4 2018 | |
| $15.7M | 3.84% | 0.29% | +260.6% | Q1 2024 | |
| MMRUSMerus N.V. | $12.6M | 3.08% | 0.18% | +48.5% | Q4 2021 |
| $10.1M | 2.48% | 0.57% | -3.1% | Q1 2022 | |
| $8.19M | 2.01% | 0.09% | +157.8% | Q1 2021 | |
| $8.08M | 1.98% | 0.19% | +110.3% | Q2 2021 | |
| NNUVLNuvalent, Inc. | $8.07M | 1.98% | 2.98% | +84.9% | Q1 2023 |
| $7.96M | 1.95% | 0.27% | +39.8% | Q2 2025 | |
| AACLXArcellx, Inc. | $7.9M | 1.94% | 0.17% | +169.3% | Q1 2023 |
| $7.84M | 1.92% | 0.34% | +178.5% | Q1 2025 | |
| $7.31M | 1.79% | 0.11% | +93.6% | Q4 2020 | |
| $7.19M | 1.76% | 0.02% | +330.8% | Q2 2020 | |
| CTCDTXCidara Therapeutics, Inc. | $6.79M | 1.66% | 0.24% | Not reported | Q3 2020 |
| $6.64M | 1.63% | 0.33% | +63.3% | Q3 2022 | |
| $6.61M | 1.62% | 0.13% | +172.7% | Q3 2023 | |
| $5.8M | 1.42% | 0.00% | +39.7% | Q1 2016 | |
| $5.32M | 1.31% | 0.03% | +19.8% | Q1 2016 | |
| $5.3M | 1.30% | 0.44% | +83.1% | Q2 2023 | |
| ATAKROAkero Therapeutics, Inc. | $5.23M | 1.28% | 0.14% | +83.5% | Q4 2020 |
| $5.04M | 1.23% | 0.45% | +41.2% | Q3 2024 | |
| $4.9M | 1.20% | 0.00% | -7.8% | Q2 2013 | |
| $4.28M | 1.05% | 0.64% | +57.0% | Q1 2021 | |
| $4.26M | 1.04% | 0.04% | +21.4% | Q2 2021 | |
| ATAPGEApogee Therapeutics, Inc. | $4.26M | 1.04% | 0.18% | +137.7% | Q1 2024 |
| $4.08M | 1.00% | 0.15% | +38.5% | Q3 2020 | |
| XRXOMAXOMA Royalty Corp | $4.07M | 1.00% | 0.86% | -7.7% | Q1 2023 |
| $4.04M | 0.99% | 0.05% | +128.5% | Q4 2024 | |
| $4.01M | 0.98% | 0.20% | +46.3% | Q2 2024 | |
| $3.79M | 0.93% | 0.06% | +33.5% | Q2 2020 | |
| $3.62M | 0.89% | 0.36% | +91.3% | Q4 2023 | |
| $3.5M | 0.86% | 0.20% | +26.9% | Q3 2020 | |
| $3.46M | 0.85% | 0.46% | +363.0% | Q4 2021 | |
| $3.38M | 0.83% | 0.20% | +198.5% | Q2 2021 | |
| $3.37M | 0.82% | 0.00% | -20.3% | Q3 2017 | |
| $3.3M | 0.81% | Not reported | +45.2% | Q1 2014 | |
| $3.3M | 0.81% | 0.11% | +80.2% | Q2 2020 | |
| APAPLSApellis Pharmaceuticals, Inc. | $3.3M | 0.81% | 0.12% | +68.2% | Q3 2021 |
| $3.13M | 0.77% | 0.07% | +159.4% | Q2 2022 | |
| $3.05M | 0.75% | 0.00% | +15.2% | Q2 2022 | |
| $3M | 0.74% | 0.01% | +68.5% | Q2 2020 | |
| ABRNAMAvidity Biosciences, Inc. | $2.86M | 0.70% | 0.04% | +60.5% | Q3 2020 |
| $2.78M | 0.68% | 0.00% | +11.7% | Q1 2024 | |
| $2.73M | 0.67% | 0.02% | Not reported | Q2 2022 | |
| $2.69M | 0.66% | 0.02% | +17.7% | Q2 2025 | |
| $2.68M | 0.66% | 0.00% | +22.3% | Q2 2013 | |
| $2.65M | 0.65% | 0.14% | +125.3% | Q3 2023 | |
| $2.5M | 0.61% | 0.00% | -8.4% | Q4 2024 | |
| $2.5M | 0.61% | 0.00% | -14.7% | Q2 2024 | |
| $2.42M | 0.59% | 0.01% | +14.5% | Q2 2016 | |
| $2.39M | 0.59% | 0.00% | +5.1% | Q2 2013 | |
Premium opens every quarter this fund has filed